Chennai-based Iswarya Fertility Center has successfully raised more than ₹350 crore (nearly $37 million) in a growth investment from healthcare investment firm OrbiMed Asia. According to reports from Mint, this significant funding round reflects growing investor interest in India's expanding fertility care market amid shifting demographic trends. The capital will be utilized to establish new centres in existing and underserved markets, strengthen clinical infrastructure, invest in digital capabilities and expand the embryology talent pipeline.
The funding will enable Iswarya to deepen its presence in existing markets and expand into underserved geographies. The company plans to continue investing in clinical excellence, medical education, and innovation as part of its growth strategy. Dr. Arun Muthuvel, managing director at Iswarya Fertility Center, stated that the company's focus over the next phase is to deepen pan-India presence, enter underserved geographies and keep raising the bar on clinical outcomes. "We will invest in our people, technology and patient experience," Muthuvel emphasized.
Iswarya Fertility Center, founded in 1986 by Dr. S. Chandralekha and Veluswamy, has grown into southern India's largest fertility network. The company currently operates more than 85 centres across eight states and has served more than 300,000 couples over the past four decades. The company offers IVF, IUI, fertility preservation, genetics and other advanced reproductive treatments, operating on a hub-and-spoke model that combines clinical depth with cost efficiency. Dr. Sunny Sharma and Arun Sadhanandham from OrbiMed noted that Iswarya has established itself as one of the country's leading fertility platforms through strong clinical outcomes, trusted brand, capital-efficient operating model and experienced leadership.
India's Sample Registration System (SRS) Statistical Report, 2024, shows the country's total fertility rate has fallen to 1.9, below the replacement rate of 2.1 required for long-term population stability. Simultaneously, rising incomes in densely populated urban centres have made consumers more willing to spend on fertility treatment, drawing increased investor interest to the sector. The funding is expected to accelerate the company's expansion plans, potentially enhancing its market share and operational capabilities in the fertility sector.
Veda Corporate Advisors acted as financial adviser to Iswarya and its promoters on the transaction. The funding represents a significant milestone for the fertility sector, with OrbiMed's healthcare expertise and shared commitment to clinical excellence making them an ideal partner for expanding access to high-quality fertility care across India and international markets over time. VP Rajan, managing director at Veda Corporate Advisors, noted that "the transaction drew strong interest from marquee investors." Investors should monitor the execution of these expansion plans and the integration of the new capital, with key areas including the company's ability to penetrate new markets and the impact of increased investments on its financial performance.
